207.94
0.01%
-0.03
After Hours:
207.94
Overview
News
Price History
Option Chain
Why LH Down?
Discussions
Forecast
Stock Split
Dividend History
Laboratory Corp. Of America Holdings stock is currently priced at $207.94, with a 24-hour trading volume of 779.99K.
It has seen a -0.01% decreased in the last 24 hours and a -2.49% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $207.3 pivot point. If it approaches the $211.3 resistance level, significant changes may occur.
Previous Close:
$207.97
Open:
$206.82
24h Volume:
779.99K
Market Cap:
$17.49B
Revenue:
$12.90B
Net Income/Loss:
$418.00M
P/E Ratio:
27.80
EPS:
7.48
Net Cash Flow:
$874.10M
1W Performance:
+3.99%
1M Performance:
-2.49%
6M Performance:
+4.68%
1Y Performance:
-10.57%
Laboratory Corp. Of America Holdings Stock (LH) Company Profile
Name
Laboratory Corp. Of America Holdings
Sector
Industry
Phone
336-229-1127
Address
358 South Main Street, Burlington, NC
Laboratory Corp. Of America Holdings Stock (LH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-09-24 | Initiated | Evercore ISI | In-line |
Jan-03-24 | Initiated | Barclays | Equal Weight |
Sep-06-23 | Initiated | HSBC Securities | Hold |
Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
Sep-19-22 | Downgrade | Argus | Buy → Hold |
Aug-22-22 | Resumed | Morgan Stanley | Overweight |
Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-11-21 | Upgrade | Argus | Hold → Buy |
Jan-11-21 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Jan-08-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
Jul-13-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jun-02-20 | Resumed | Deutsche Bank | Buy |
May-15-20 | Upgrade | Mizuho | Neutral → Buy |
Apr-29-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jan-08-20 | Initiated | Wells Fargo | Overweight |
Jul-16-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
Jun-21-19 | Upgrade | Deutsche Bank | Hold → Buy |
Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
Jan-17-19 | Initiated | UBS | Buy |
Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Dec-03-18 | Downgrade | Craig Hallum | Buy → Hold |
Oct-30-18 | Downgrade | Argus | Buy → Hold |
Oct-25-18 | Downgrade | Canaccord Genuity | Buy → Hold |
Oct-19-18 | Resumed | BofA/Merrill | Buy |
Jun-07-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
May-01-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
Mar-23-18 | Initiated | Argus | Buy |
View All
Laboratory Corp. Of America Holdings Stock (LH) Latest News
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Zacks Investment Research
Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Exploring Analyst Estimates for Labcorp (LH) Q1 Earnings, Beyond Revenue and EPS
Zacks Investment Research
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
Zacks Investment Research
Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised)
Zacks Investment Research
Why Labcorp (LH) Could Beat Earnings Estimates Again
Zacks Investment Research
Laboratory Corp. Of America Holdings Stock (LH) Financials Data
Laboratory Corp. Of America Holdings (LH) Revenue 2024
LH reported a revenue (TTM) of $12.90 billion for the quarter ending December 31, 2023, a +2.24% rise year-over-year.
Laboratory Corp. Of America Holdings (LH) Net Income 2024
LH net income (TTM) was $418.00 million for the quarter ending December 31, 2023, a -67.32% decrease year-over-year.
Laboratory Corp. Of America Holdings (LH) Cash Flow 2024
LH recorded a free cash flow (TTM) of $874.10 million for the quarter ending December 31, 2023, a -42.74% decrease year-over-year.
Laboratory Corp. Of America Holdings (LH) Earnings per Share 2024
LH earnings per share (TTM) was $4.65 for the quarter ending December 31, 2023, a -66.45% decline year-over-year.
Laboratory Corp. Of America Holdings Stock (LH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Schroeder Mark S | EVP, Pres Diagnostics & COO |
Apr 01 '24 |
Sale |
217.29 |
6,477 |
1,407,387 |
5,036 |
Summy Amy B. | EVP, Chief Marketing Officer |
Apr 01 '24 |
Sale |
217.29 |
3,500 |
760,515 |
3,975 |
van der Vaart Sandra D | EVP, Chief Legal Officer |
Mar 28 '24 |
Sale |
216.74 |
3,553 |
770,077 |
7,637 |
Schroeder Mark S | EVP, Pres Diagnostics & COO |
Mar 07 '24 |
Option Exercise |
117.09 |
2,119 |
248,114 |
10,084 |
Schroeder Mark S | EVP, Pres Diagnostics & COO |
Mar 07 '24 |
Sale |
218.45 |
5,048 |
1,102,736 |
5,036 |
Summy Amy B. | EVP, Chief Marketing Officer |
Mar 07 '24 |
Sale |
218.45 |
227 |
49,588 |
3,859 |
EISENBERG GLENN A | Chief Financial Officer, EVP |
Feb 21 '24 |
Option Exercise |
163.63 |
14,054 |
2,299,656 |
58,099 |
EISENBERG GLENN A | Chief Financial Officer, EVP |
Feb 21 '24 |
Sale |
215.97 |
34,504 |
7,451,866 |
23,595 |
DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl |
Feb 21 '24 |
Sale |
215.49 |
500 |
107,745 |
3,401 |
van der Vaart Sandra D | EVP, Chief Legal Officer |
Feb 13 '24 |
Sale |
226.45 |
237 |
53,669 |
7,637 |
About Laboratory Corp. Of America Holdings
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests, as well as with Baptist Health. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Cap:
|
Volume (24h):